263 related articles for article (PubMed ID: 22196480)
1. Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction.
Kawamoto SA; Coleska A; Ran X; Yi H; Yang CY; Wang S
J Med Chem; 2012 Feb; 55(3):1137-46. PubMed ID: 22196480
[TBL] [Abstract][Full Text] [Related]
2. Decoding the dynamics of BCL9 triazole stapled peptide.
Gaikwad V; Choudhury AR; Chakrabarti R
Biophys Chem; 2024 Apr; 307():107197. PubMed ID: 38335808
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.
Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J
Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961
[TBL] [Abstract][Full Text] [Related]
4. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR
Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction.
Kawamoto SA; Thompson AD; Coleska A; Nikolovska-Coleska Z; Yi H; Wang S
Biochemistry; 2009 Oct; 48(40):9534-41. PubMed ID: 19715304
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of a beta-catenin/BCL9/Tcf4 complex.
Sampietro J; Dahlberg CL; Cho US; Hinds TR; Kimelman D; Xu W
Mol Cell; 2006 Oct; 24(2):293-300. PubMed ID: 17052462
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Zhang M; Wang Z; Zhang Y; Guo W; Ji H
J Med Chem; 2018 Apr; 61(7):2989-3007. PubMed ID: 29566337
[TBL] [Abstract][Full Text] [Related]
8. AlphaScreen selectivity assay for β-catenin/B-cell lymphoma 9 inhibitors.
Zhang M; Wisniewski JA; Ji H
Anal Biochem; 2015 Jan; 469():43-53. PubMed ID: 25312469
[TBL] [Abstract][Full Text] [Related]
9. Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with beta-catenin.
Sustmann C; Flach H; Ebert H; Eastman Q; Grosschedl R
Mol Cell Biol; 2008 May; 28(10):3526-37. PubMed ID: 18347063
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Wang Z; Zhang M; Luo W; Zhang Y; Ji H
J Med Chem; 2021 May; 64(9):5886-5904. PubMed ID: 33902288
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.
Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q
Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283
[TBL] [Abstract][Full Text] [Related]
12. Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis.
Trabocchi A; Menchi G; Cini N; Bianchini F; Raspanti S; Bottoncetti A; Pupi A; Calorini L; Guarna A
J Med Chem; 2010 Oct; 53(19):7119-28. PubMed ID: 20809642
[TBL] [Abstract][Full Text] [Related]
13. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
14. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.
El-Hage P; Petitalot A; Monsoro-Burq AH; Maczkowiak F; Driouch K; Formstecher E; Camonis J; Sabbah M; Bièche I; Lidereau R; Lallemand F
Mol Cancer Res; 2015 May; 13(5):902-12. PubMed ID: 25678599
[TBL] [Abstract][Full Text] [Related]
15. Efficient microwave assisted synthesis of novel 1,2,3-triazole-sucrose derivatives by cycloaddition reaction of sucrose azides and terminal alkynes.
Potewar TM; Petrova KT; Barros MT
Carbohydr Res; 2013 Sep; 379():60-7. PubMed ID: 23872329
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Li Z; Zhang M; Teuscher KB; Ji H
J Med Chem; 2021 Aug; 64(15):11195-11218. PubMed ID: 34270257
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of quercetin derivatives as novel β-catenin/B-cell lymphoma 9 protein-protein interaction inhibitors.
Shen LA; Peng X; Bao Y; Liu C; Zhang H; Li J; Zhu D; Zhang Q
Eur J Med Chem; 2023 Feb; 247():115075. PubMed ID: 36599228
[TBL] [Abstract][Full Text] [Related]
18. Facile entry into triazole fused heterocycles via sulfamidate derived azido-alkynes.
Sai Sudhir V; Phani Kumar NY; Nasir Baig RB; Chandrasekaran S
J Org Chem; 2009 Oct; 74(19):7588-91. PubMed ID: 19725506
[TBL] [Abstract][Full Text] [Related]
19. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.
de la Roche M; Rutherford TJ; Gupta D; Veprintsev DB; Saxty B; Freund SM; Bienz M
Nat Commun; 2012 Feb; 3():680. PubMed ID: 22353711
[TBL] [Abstract][Full Text] [Related]
20. New ZW4864 Derivatives as Small-Molecule Inhibitors for the β-Catenin/BCL9 Protein-Protein Interaction.
Wang Z; Zhang M; Thompson HM; Ji H
ACS Med Chem Lett; 2022 May; 13(5):865-870. PubMed ID: 35586435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
